Amgen: Japan Supreme Court Rejects Sanofi Appeal on PCSK9 Patent

Supreme Court of Japan on April 24 upheld decision that Sanofi’s Praluent infringes Amgen’s patents covering a narrow class of antibodies that inhibit the PCSK9 human protein, Amgen says in statement.

• Court ruling means Sanofi is prohibited from manufacturing, distributing, importing, or offering to distribute Praluent in Japan
• Amgen KK, the marketing authorization holder of PCSK9 inhibitor Repatha, will implement injunction

To view the source of this information click here

To contact the reporter on this story:
Michael Sin in Hong Kong at msin12@bloomberg.net

To contact the editor responsible for this story:
Ryan Lovdahl at rlovdahl@bloomberg.net

© 2020 Bloomberg L.P. ...